{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:28:01Z","timestamp":1790962081478,"version":"4.1.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Congestive heart failure (CHF) and atrial fibrillation (AF) frequently coexist and are associated with increased risk of cardiovascular events.<\/jats:p>\n            <jats:p>To compare baseline characteristics, comorbidities and pharmacotherapy in AF patients with concomitant CHF to those without CHF.<\/jats:p>\n            <jats:p>The study included 3506 real-life AF patients with (37.1%) and without CHF \u2014 participants of the multicentre, retrospective MultiCenter expeRience in AFib patients Treated with OAC (CRAFT) trial (NCT02987062).<\/jats:p>\n            <jats:p>All patients were treated with non-vitamin K antagonist oral anticoagulants (NOAC) or vitamin K antagonists (VKA). The frequency of NOAC among patients with and without CHF was 45.6% and 43.2%, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.17). Patients with CHF were older (73.3 vs 64.7 years, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;.001), less likely to be women (37.4% vs 42%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.007), had higher CHA2DS2-VASc score (3.8\u200a\u00b1\u200a1.7 vs 2.6\u200a\u00b1\u200a1.8, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;.001), more often had permanent AF (53.0% vs 13.4%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;.001), chronic obstructive pulmonary disease (16.7% vs 4.9%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;.001), coronary artery disease (64.3% vs 29.8%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;.001), peripheral vascular disease (65.3% vs 31.4%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;.001), chronic kidney disease (43.1% vs 10.0%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;.001), liver fibrosis (5.7% vs 2.6%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;.001), neoplasm (9.6% vs 7.3%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.05), history of composite of stroke, transient ischemic attack or systemic embolization (16.2% vs 10.7%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;.001), pacemaker (27.4% vs 22.1%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.004), implantable cardioverter-defibrillator (22.7% vs 0.8%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;.001) or transaortic valve implantation (4.0% vs 0.8%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;.001), cardiac resynchronization therapy (8.7% vs 0.3%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;.001), composite of kidney transplantation, hemodialysis or creatinine level\u200a&gt;\u200a2.26\u200amg\/dL (3.6% vs 0.8%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;.001) and had less often hypertension (69.4% vs 72.5%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.05).<\/jats:p>\n            <jats:p>Patients with AF and CHF had a higher thromboembolic risk and had more concomitant diseases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000013074","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T21:26:40Z","timestamp":1541539600000},"page":"e13074","source":"Crossref","is-referenced-by-count":11,"title":["Clinical characteristics and thromboembolic risk of atrial fibrillation patients with and without congestive heart failure. Results from the CRATF study"],"prefix":"10.1097","volume":"97","author":[{"given":"Pawe\u0142","family":"Balsam","sequence":"first","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Gawa\u0142ko","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Peller","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Tymi\u0144ska","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Oziera\u0144ski","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyna","family":"Zaleska","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"\u017bukowska","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Szepietowska","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kacper","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"Cardiology Unit, John Paul II Western Hospital, Grodzisk Mazowiecki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Grabowski","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Borkowski","sequence":"additional","affiliation":[{"name":"\u201cOrlik\u201d Medical Clinic, Warsaw, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Ko\u0142towski","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Praska-Oginska","sequence":"additional","affiliation":[{"name":"Cardiology Unit, John Paul II Western Hospital, Grodzisk Mazowiecki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Zaboyska","sequence":"additional","affiliation":[{"name":"Cardiology Unit, John Paul II Western Hospital, Grodzisk Mazowiecki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Opolski","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Bednarski","sequence":"additional","affiliation":[{"name":"Cardiology Unit, John Paul II Western Hospital, Grodzisk Mazowiecki"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/clc.20138","article-title":"Update on atrial fibrillation: part 1","volume":"31","author":"Savelieva","year":"2008","journal-title":"Clin Cardiol"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ejhf.254","article-title":"Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational research programme pilot survey on atrial fibrillation","volume":"17","author":"Lip","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: preventing disease and death worldwide","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Failure"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1161\/01.CIR.0000072767.89944.6E","article-title":"Temporal relation of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study","volume":"107","author":"Wang","year":"2003","journal-title":"Circulation"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1161\/CIRCHEARTFAILURE.111.965681","article-title":"Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure","volume":"5","author":"Mountantonakis","year":"2012","journal-title":"Circ Heart Fail"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1161\/CIRCULATIONAHA.114.013760","article-title":"Risk of stroke in chronic heart failure patients without atrial fibrillation: analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Insufcienza Cardiaca-Heart Failure (GISSI-HF) Trials","volume":"131","author":"Abdul-Rahim","year":"2015","journal-title":"Circulation"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.5603\/KP.2016.0141","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"74","author":"Ponikowski","year":"2016","journal-title":"Kardiol Pol"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood-2009-02-207928","article-title":"Warfarin Associated Research Projects and other EnDeavors (WARPED) Consortium. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy","volume":"114","author":"Witt","year":"2009","journal-title":"Blood"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1538-7836.2010.03756.x","article-title":"Twelve month outcomes and predictors of very stable INR control in prevalent warfarin users","volume":"8","author":"Witt","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/ejhf.343","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials","volume":"17","author":"Xiong","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"640723","DOI":"10.1155\/2013\/640723","article-title":"Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups","volume":"2013","author":"G\u00f3mez-Outes","year":"2013","journal-title":"Thrombosis"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"e003725","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R16-20230915","first-page":"823","article-title":"Comparison of different oral anticoagulant regimens in patients with atrial fibrillation undergoing ablation or cardioversion","volume":"127","author":"Gawa\u0142ko","year":"2017","journal-title":"Pol Arch Intern Med"},{"key":"R17-20230915","first-page":"979","article-title":"New oral anticoagulants in the prevention of embolic complications in patients with atrial fibrillation","volume":"70","author":"Pruszczyk","year":"2012","journal-title":"Kardiol Pol"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"889","DOI":"10.5603\/KP.a2018.0027","article-title":"Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study","volume":"76","author":"Balsam","year":"2018","journal-title":"Kardiol Pol"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/europace\/eut373","article-title":"A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational research programme atrial fibrillation (EORP-AF) pilot general registry","volume":"16","author":"Lip","year":"2014","journal-title":"Europace"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/eurheartj\/ehi694","article-title":"Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades","volume":"27","author":"Miyasaka","year":"2006","journal-title":"Eur Heart J"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jchf.2017.04.004","article-title":"Modifiable risk factors for incident heart failure in atrial fibrillation","volume":"5","author":"Chatterjee","year":"2017","journal-title":"JACC Heart Fail"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5603\/CJ.a2016.0004","article-title":"Anti-thromboembolic strategies in atrial fibrillation","volume":"23","author":"Cocco","year":"2016","journal-title":"Cardiol J"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5603\/CJ.a2015.0053","article-title":"New concepts in the therapy of atrial fibrillation","volume":"23","author":"Cocco","year":"2016","journal-title":"Cardiol J"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1161\/01.CIR.0000145172.55640.93","article-title":"Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin","volume":"110","author":"Gage","year":"2004","journal-title":"Circulation"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5603\/KP.a2015.0180","article-title":"Clinical characteristics and predictors of one-year outcome of heart failure patients with atrial fibrillation compared to heart failure patients in sinus rhythm","volume":"74","author":"Oziera\u0144ski","year":"2016","journal-title":"Kardiol Pol"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jacc.2009.01.055","article-title":"Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the euro heart survey on atrial fibrillation","volume":"53","author":"Nieuwlaat","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R28-20230915","first-page":"392","article-title":"Epidemiology and management of coexisting heart failure and atrial fibrillation in an outpatient setting","volume":"121","author":"Rewiuk","year":"2011","journal-title":"Pol Arch Med Wewn"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"176","DOI":"10.5603\/CJ.a2017.0003","article-title":"Pilot of a Computerised Antithrombotic Risk Assessment Tool Version 2 (CARATV2.0) for stroke prevention in atrial fibrillation","volume":"24","author":"Wang","year":"2017","journal-title":"Cardiol J"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"223","DOI":"10.5603\/CJ.2012.0043","article-title":"Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation","volume":"19","author":"D\u0105browski","year":"2012","journal-title":"Cardiol J"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of beta-blockers in patients with heart failure plus atrial brillation: an individual-patient data meta-analysis","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study","volume":"129","author":"Lamberts","year":"2014","journal-title":"Circulation"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5603\/KP.a2015.0112","article-title":"Predictors of one-year outcome in patients hospitalised for heart failure: results from the Polish part of the Heart Failure Pilot Survey of the European Society of Cardiology","volume":"74","author":"Balsam","year":"2016","journal-title":"Kardiol Pol"},{"key":"R34-20230915","first-page":"1053","volume":"15","author":"Ferreira","year":"2013","journal-title":"RE-LY Investigators Dabigatran compared with warfarin in24 patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial Eur J Heart Fail"},{"key":"R35-20230915","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.113.000212","article-title":"Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF","volume":"6","author":"van Diepen","year":"2013","journal-title":"Circ Heart Fail"},{"key":"R36-20230915","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5603\/CJ.2012.0002","article-title":"ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?","volume":"19","author":"Tendera","year":"2012","journal-title":"Cardiol J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201811090-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T21:09:12Z","timestamp":1694812152000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201811090-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":36,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013074","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}